4.7 Article

Deubiquitinase BAP1 regulates stability of BRCA1 protein and inactivates the NF-xB signaling to protect mice from sepsis-induced acute kidney injury

期刊

CHEMICO-BIOLOGICAL INTERACTIONS
卷 382, 期 -, 页码 -

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.cbi.2023.110621

关键词

BAP1; BRCA1; NF-xB; Sepsis; Acute kidney injury

向作者/读者索取更多资源

This study investigates the role of Breast cancer susceptibility protein 1-associated protein 1 (BAP1) in sepsis-induced acute kidney injury (AKI). The findings suggest that BAP1 can protect against AKI by enhancing the stability of BRCA1 protein and inactivating the NF-xB signaling pathway.
Sepsis and its associated organ dysfunction syndrome is a leading cause of death in critically ill patients. Breast cancer susceptibility protein 1 (BRCA1)-associated protein 1 (BAP1) is a potential regulator in immune regulation and inflammatory responses. This study aims to investigate the function of BAP1 in sepsis-induced acute kidney injury (AKI). A mouse model with sepsis-induced AKI was induced by cecal ligation and puncture, and renal tubular epithelial cells (RTECs) were treated with lipopolysaccharide (LPS) to mimic an AKI condition in vitro. BAP1 was significantly poorly expressed in the kidney tissues of model mice and the LPS-treated RTECs. Artificial upregulation of BAP1 ameliorated the pathological changes, tissue injury and inflammatory responses in kidney tissues of the mice, and it reduced the LPS-induced injury and apoptosis of the RTECs. BAP1 was found to interact with BRCA1 and enhance stability of BRCA1 protein through deubiquitination modification. Further downregulation of BRCA1 activated the nuclear factor-kappa B (NF-xB) signaling pathway and blocked the protective roles of BAP1 in sepsis-induced AKI. In conclusion, this study demonstrates that BAP1 protects mice from sepsis-induced AKI through enhancing stability of BRCA1 protein and inactivating the NF-xB signaling.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据